# Clifford S Cho

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 74 papers | 1,527 citations | 22 h-index | 37 g-index |
| 79 ext. papers | 1,950 ext. citations | 3.5 avg, IF | 4.46 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 74 | Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. *Annals of Surgical Oncology*, **2017**, 24, 2023-2030 | 3.1 | 163 |
| 73 | Preoperative radiographic assessment of hepatic steatosis with histologic correlation. *Journal of the American College of Surgeons*, **2008**, 206, 480-8 | 4.4 | 80 |
| 72 | Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. *Cancer*, **2008**, 113, 126-34 | 6.4 | 75 |
| 71 | Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis. *Journal of Surgical Oncology*, **2018**, 117, 644-650 | 2.8 | 73 |
| 70 | Preoperative classification of pancreatic cystic neoplasms: the clinical significance of diagnostic inaccuracy. *Annals of Surgical Oncology*, **2013**, 20, 3112-9 | 3.1 | 72 |
| 69 | Effect of Perioperative Transfusion on Recurrence and Survival after Gastric Cancer Resection: A 7-Institution Analysis of 765 Patients from the US Gastric Cancer Collaborative. *Journal of the American College of Surgeons*, **2015**, 221, 767-77 | 4.4 | 56 |
| 68 | Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms: A Multicenter Study. *JAMA Surgery*, **2017**, 152, 19-25 | 5.4 | 52 |
| 67 | Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. *Nature Cancer*, **2020**, 1, 1097-1112 | 15.4 | 52 |
| 66 | Conditional survival after surgical resection of gastric cancer: a multi-institutional analysis of the us gastric cancer collaborative. *Annals of Surgical Oncology*, **2015**, 22, 557-64 | 3.1 | 51 |
| 65 | A nomogram to predict overall survival and disease-free survival after curative resection of gastric adenocarcinoma. *Annals of Surgical Oncology*, **2015**, 22, 1828-35 | 3.1 | 50 |
| 64 | Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. *Annals of Surgical Oncology*, **2016**, 23, 2398-408 | 3.1 | 50 |
| 63 | Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique?. *Annals of Surgery*, **2011**, 253, 975-80 | 7.8 | 49 |
| 62 | Does postoperative drain amylase predict pancreatic fistula after pancreatectomy?. *Journal of the American College of Surgeons*, **2014**, 218, 978-87 | 4.4 | 44 |
| 61 | A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. *Annals of Surgery*, **2019**, 270, 422-433 | 7.8 | 33 |
| 60 | Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis. *Annals of Surgery*, **2021**, 273, 587-594 | 7.8 | 31 |
| 59 | Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7-institution study of the U.S. gastric cancer collaborative. *Journal of Surgical Oncology*, **2016**, 113, 750-5 | 2.8 | 29 |
| 58 | Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice. *Journal of Immunotherapy*, **2015**, 38, 54-61 | 5 | 28 |

| | | | |
|---|---|---|---|
| 57 | The relationship of blood transfusion with peri-operative and long-term outcomes after major hepatectomy for metastatic colorectal cancer: a multi-institutional study of 456 patients. *Hpb*, **2016**, 18, 192-199 | 3.8 | 28 |
| 56 | Value of primary operative drain placement after major hepatectomy: a multi-institutional analysis of 1,041 patients. *Journal of the American College of Surgeons*, **2015**, 220, 396-402 | 4.4 | 27 |
| 55 | The importance of the proximal resection margin distance for proximal gastric adenocarcinoma: A multi-institutional study of the US Gastric Cancer Collaborative. *Journal of Surgical Oncology*, **2015**, 112, 203-7 | 2.8 | 24 |
| 54 | Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. *Annals of Surgical Oncology*, **2019**, 26, 2517-2524 | 3.1 | 22 |
| 53 | Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. *Annals of Surgical Oncology*, **2016**, 23, 1203-11 | 3.1 | 22 |
| 52 | An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A seven-institution analysis of 837 patients from the U.S. gastric cancer collaborative. *Journal of Surgical Oncology*, **2015**, 112, 195-202 | 2.8 | 21 |
| 51 | Proctocolectomy-ileal pouch-anal anastomosis for ulcerative colitis after liver transplantation for primary sclerosing cholangitis: a multi-institutional analysis. *Journal of Gastrointestinal Surgery*, **2008**, 12, 1221-6 | 3.3 | 21 |
| 50 | Are the Current Guidelines for the Surgical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas Adequate? A Multi-Institutional Study. *Journal of the American College of Surgeons*, **2017**, 224, 461-469 | 4.4 | 20 |
| 49 | The Prognostic Value of Signet-Ring Cell Histology in Resected Gastric Adenocarcinoma. *Annals of Surgical Oncology*, **2015**, 22 Suppl 3, S832-9 | 3.1 | 20 |
| 48 | The effect of preoperative renal insufficiency on postoperative outcomes after major hepatectomy: a multi-institutional analysis of 1,170 patients. *Journal of the American College of Surgeons*, **2014**, 219, 914-22 | 4.4 | 20 |
| 47 | Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. *Surgery*, **2017**, 162, 285-294 | 3.6 | 19 |
| 46 | Risk stratification for readmission after major hepatectomy: development of a readmission risk score. *Journal of the American College of Surgeons*, **2015**, 220, 640-8 | 4.4 | 19 |
| 45 | Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma. *Annals of Surgical Oncology*, **2010**, 17, 371-6 | 3.1 | 18 |
| 44 | The conundrum of Surgery, **2019**, 166, 15-21 | 3.6 | 16 |
| 43 | Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. *World Journal of Surgery*, **2017**, 41, 224-231 | 3.3 | 16 |
| 42 | In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells. *PLoS ONE*, **2019**, 14, e0223339 | 3.7 | 15 |
| 41 | Discordance of Histologic Grade Between Primary and Metastatic Neuroendocrine Carcinomas. *Annals of Surgical Oncology*, **2015**, 22 Suppl 3, S817-21 | 3.1 | 14 |
| 40 | Preoperative Helicobacter pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma. *Annals of Surgical Oncology*, **2016**, 23, 1225-33 | 3.1 | 13 |

| | | | |
|---|---|---|---|
| 39 | Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multi-institutional analysis. *Journal of Surgical Oncology*, **2019**, 120, 1080-1086 | 2.8 | 13 |
| 38 | Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. *Journal of Gastrointestinal Surgery*, **2019**, 23, 122-134 | 3.3 | 13 |
| 37 | Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors. *Journal of Gastrointestinal Surgery*, **2019**, 23, 651-658 | 3.3 | 12 |
| 36 | Value of Peritoneal Drain Placement After Total Gastrectomy for Gastric Adenocarcinoma: A Multi-institutional Analysis from the US Gastric Cancer Collaborative. *Annals of Surgical Oncology*, **2015**, 22 Suppl 3, S888-97 | 3.1 | 12 |
| 35 | Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. *Journal of Surgical Oncology*, **2020**, 121, 1201-1208 | 2.8 | 12 |
| 34 | Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice. *Cancer Immunology, Immunotherapy*, **2016**, 65, 601-11 | 7.4 | 11 |
| 33 | Robotically Assisted Sonic Therapy (RAST) for Noninvasive Hepatic Ablation in a Porcine Model: Mitigation of Body Wall Damage with a Modified Pulse Sequence. *CardioVascular and Interventional Radiology*, **2019**, 42, 1016-1023 | 2.7 | 10 |
| 32 | Suppression of T-cell expansion by melanoma is exerted on resting cells. *Annals of Surgical Oncology*, **2011**, 18, 3848-57 | 3.1 | 10 |
| 31 | Readmission Following Gastric Cancer Resection: Risk Factors and Survival. *Journal of Gastrointestinal Surgery*, **2016**, 20, 1284-94 | 3.3 | 10 |
| 30 | Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion. *Cellular Immunology*, **2011**, 271, 104-9 | 4.4 | 9 |
| 29 | The diagnosis of pancreatic mucinous cystic neoplasm and associated adenocarcinoma in males: An eight-institution study of 349 patients over 15 years. *Journal of Surgical Oncology*, **2017**, 115, 784-787 | 2.8 | 8 |
| 28 | Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. *Journal of Surgical Oncology*, **2020**, 121, 1067-1073 | 2.8 | 8 |
| 27 | Effects of Histotripsy on Local Tumor Progression in an Orthotopic Rodent Liver Tumor Model. *BME Frontiers*, **2020**, 2020, | 4.4 | 8 |
| 26 | Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. *Surgery*, **2019**, 165, 657-663 | 3.6 | 7 |
| 25 | Memory T cells are uniquely resistant to melanoma-induced suppression. *Cancer Immunology, Immunotherapy*, **2013**, 62, 149-59 | 7.4 | 6 |
| 24 | Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model **2018**, 6, 41 | | 5 |
| 23 | Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group. *Neuroendocrinology*, **2021**, 111, 129-138 | 5.6 | 5 |
| 22 | Immunotherapy for pancreatic ductal adenocarcinoma. *Journal of Surgical Oncology*, **2021**, 123, 751-759 | 2.8 | 5 |

| | | | |
|---|---|---|---|
| 21 | Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis. *Cancer*, **2021**, 127, 1266-1274 | 6.4 | 4 |
| 20 | A multi-institutional analysis of 429 patients undergoing major hepatectomy for colorectal cancer liver metastases: The impact of concomitant bile duct resection on survival. *Journal of Surgical Oncology*, **2015**, 112, 524-8 | 2.8 | 3 |
| 19 | Impact of Histotripsy on Development of Intrahepatic Metastases in a Rodent Liver Tumor Model.. *Cancers*, **2022**, 14, | 6.6 | 3 |
| 18 | Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group. *Hpb*, **2020**, 22, 1042-1050 | 3.8 | 2 |
| 17 | Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis. *Journal of Gastrointestinal Surgery*, **2021**, 25, 1805-1814 | 3.3 | 1 |
| 16 | Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group. *Annals of Surgical Oncology*, **2020**, 27, 3915-3923 | 3.1 | 1 |
| 15 | Systemic Chemotherapy for Resectable Hepatic Colorectal Metastases: Adjuvant, Neoadjuvant, or Not at All?. *Current Surgery Reports*, **2014**, 2, 1 | 0.5 | 1 |
| 14 | The oncologic significance of postoperative complications after hepatic colorectal metastasectomy: biology, technique, or statistical quirk?. *Journal of Surgical Research*, **2012**, 172, 80-2 | 2.5 | 1 |
| 13 | Surgical resection of hepatocellular carcinoma: less is more?. *Journal of Surgical Research*, **2009**, 157, 155-7 | 2.5 | 1 |
| 12 | Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors. *Annals of Surgical Oncology*, **2020**, 27, 3147-3153 | 3.1 | 1 |
| 11 | Significance and innovation: cornerstones of a successful grant application. *Surgery*, **2021**, 170, 1080-1082 | 3.6 | 1 |
| 10 | Prognostication systems as applied to primary and metastatic hepatic malignancies. *Surgical Oncology Clinics of North America*, **2015**, 24, 41-56 | 2.7 | 0 |
| 9 | Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. *Journal of Surgical Oncology*, **2020**, 122, 442-449 | 2.8 | 0 |
| 8 | Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer.. *Neoplasia*, **2022**, 25, 53-61 | 6.4 | 0 |
| 7 | Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. *Annals of Surgical Oncology*, **2021**, 1 | 3.1 | 0 |
| 6 | The Hand-Assisted Laparoscopic Approach to Resection of Pancreatic Mucinous Cystic Neoplasms: An Underused Technique?. *American Surgeon*, **2018**, 84, 56-62 | 0.8 | |
| 5 | ASO Visual Abstract: Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. *Annals of Surgical Oncology*, **2021**, 28, 734-735 | 3.1 | |
| 4 | In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells **2019**, 14, e0223339 | | |

3 In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells **2019**, 14, e0223339

2 In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells **2019**, 14, e0223339

1 In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells **2019**, 14, e0223339